RPWA
TEVA icon

Regent Peak Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Regent Peak Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-580
Closed -$6K – 889
2020
Q4 		$6K Buy
+580
New +$5.56K ﹤0.01% 643

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Regent Peak Wealth Advisors's TEVA Position: Q1 2021 in Review

Regent Peak Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 580 shares — an estimated $6K sold.

Regent Peak Wealth Advisors first reported a position in TEVA in Q4 2020 and held it in 1 quarter. The position peaked at $6K in Q4 2020. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • Regent Peak Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Regent Peak Wealth Advisors sold 580 Teva Pharmaceuticals shares in Q1 2021, an estimated $6K.
  • Regent Peak Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Regent Peak Wealth Advisors's Teva Pharmaceuticals position peaked at $6K in Q4 2020.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Regent Peak Wealth Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.